CD8A and neoplasm: Studies have shown that PARPi can upregulate PD-L1 expression on tumor cells and increase T cell infiltration, particularly CD8+ T cells, in the tumor microenvironment, thereby enhancing tumor sensitivity to immune checkpoint inhibitors.